Newegg Commerce Inc
Change company Symbol lookup
Select an option...
NEGG Newegg Commerce Inc
CHFI China Finance Inc
SU Suncor Energy Inc
CUBI Customers Bancorp Inc
SMIT Schmitt Industries Inc
BA Boeing Co
AMSWA American Software Inc
V Visa Inc
SVFB SVF Investment Corp 2
DMO Western Asset Mortgage Opportunity Fund Inc

Consumer Discretionary : Internet & Direct Marketing Retail | Small Cap Value
Company profile

Newegg Commerce, Inc. is a technology-focused e-commerce company in North America. The Company has developed an online marketplace that delivers value to consumers, brands, and sellers in the technology products sector. It operates business-to-consumer (B2C) platforms, business-to-business (B2B) operations, and other online platforms. Its B2C platform focuses on selling information technology (IT) products, through its platforms, namely Newegg.Com, Newegg.Ca, And Newegg Global. The Company’s B2B platform focuses on providing office and IT equipment, through its platform. Its platforms offer a suite of e-commerce solutions, including product listing, fulfillment, marketing, customer service and other value-added tools and services. The Company’s product categories offered through its platforms, such as computer system, components, electronics, gaming, networking and smart home, office solutions, software and services, automotive and industrial, and health and sports.

Closing Price
Day's Change
0.06 (3.06%)
B/A Size
Day's High
Day's Low

10-day average volume:

FDA backs annual COVID vaccine for Americans with strain to be decided midyear

7:29 am ET January 25, 2023 (MarketWatch)

By Ciara Linnane

The next coronavirus strain may come from China if current wave leads to more natural immunity, says the journal Nature

The Food and Drug Administration is recommending that the U.S. decide each June which SARS-CoV-2 strains should be included in an annual fall booster shot.

Doing so would allow updated COVID-19 vaccines to be ready for distribution "no later than September" each year, according to documents published by the regulator.

The FDA's Vaccines and Related Biological Products Advisory Committee is set to meet Thursday to discuss the proposal, as well as other issues, including whether the same strain should be included in the primary series of shots and in booster doses.

The news comes as the seven-day average of new U.S. COVID cases stood at 46,418 on Monday, according to a New York Times tracker, down 29% from two weeks ago. The daily average for hospitalizations was down 22% to 37,089. The average for deaths was 487, up 4% from two weeks ago.

Cases are now rising in just five states: Alaska, Tennessee, Illinois, Kentucky and Missouri. On a per capita basis, Tennessee leads with 41 new cases per 100,000 residents, followed by Rhode Island at 27.

New York and New Jersey, which were recent hot spots, are showing signs of recovery, with cases down about 30% in both states, the trackers noted.

Coronavirus Update: MarketWatch's daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

Other COVID-19 news you should know about:

-- The next variant of the coronavirus that causes COVID could come from China if a current wave of infections allows more people to acquire immunity. That could force the virus to find new ways to evade immune protections, according to the journal Nature It is crucial that variants continue to be tracked, but scientists question how quickly the next variant of concern will be detected as many countries wind down surveillance efforts. That has been a repeated complaint from the World Health Organization in its weekly epidemiological updates, which caution that data are being distorted as countries pull back on surveillance and testing.

-- A Mississippi doctor who leads a group of physicians opposed to COVID-19 vaccine mandates has filed paperwork to challenge Mississippi Gov. Tate Reeves in the state's Republican primary, the Associated Press reported. John Witcher is the only Republican other than Reeves who has entered the gubernatorial primary so far. He's best known for founding Mississippi Against Mandates, the group opposed to requiring COVID vaccines. Witcher has said he was fired from a Mississippi hospital in 2021 after switching patients' COVID-19 medication to ivermectin, an antiparasite drug that is not authorized by the FDA for use against the novel coronavirus and which research shows is not effective.

-- Johnson & Johnson's (JNJ) fourth-quarter profit fell 25.7% to $3.52 billion, or $1.33 a share, from $4.74 billion, or $1.77 a share, in the same period last year. The company's adjusted net income in the latest quarter totaled $2.35 a share, ahead of the Wall Street analyst estimate of $2.23 a share, according to FactSet data. The drug company's revenue fell 4.4% to $23.71 billion, slightly short of the Wall Street revenue target of $23.896 billion. The company said the decline was due to reduced COVID vaccine sales.

Here's what the numbers say:

The global tally of confirmed cases of COVID-19 topped 669.1 million on Monday, while the death toll rose above 6.74 million, according to data aggregated by Johns Hopkins University.

The U.S. leads the world with 102 million cases and 1,104,390 fatalities.

The Centers for Disease Control and Prevention's tracker shows that 229.5 million people living in the U.S., equal to 69.1% of the total population, are fully vaccinated, meaning they have had their primary shots.

So far, just 50.7 million Americans, equal to 15.3% of the overall population, have had the updated COVID booster that targets both the original virus and the omicron variants.

-Ciara Linnane


(END) Dow Jones Newswires

January 25, 2023 07:29 ET (12:29 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.